TIL THERAPY FOR
MELANOMA
Lifileucel (Amtagvi) is the first FDA-approved TIL therapy โ designed for advanced melanoma patients who have already failed immunotherapy.
Key Clinical Data โ Melanoma
- ~31%Objective Response RateIn heavily pre-treated patients who had already failed anti-PD-1 immunotherapy in the pivotal C-144-01 trial.
- Feb 2024FDA Approval DateLifileucel (Amtagvi) โ the first TIL therapy approved anywhere in the world.
- >1 yrDurable ResponsesA subset of responding patients maintained responses for more than one year after a single course of treatment.
Why Melanoma Responds to TIL Therapy
Melanoma carries one of the highest mutational burdens of any cancer type. Each genetic error creates a potential immune target. TIL cells โ which developed inside the tumor โ have already been exposed to those targets and built immune memory around the specific features of that particular cancer.
โMelanoma biology made it the natural starting point for TIL therapy โ and the clinical data confirmed it.โ
Who Is Lifileucel Approved For?
Patients typically considered for TIL therapy in melanoma meet specific criteria that reflect the approved indication.
Metastatic or unresectable disease
Locally advanced or metastatic melanoma not amenable to curative surgery.
Prior anti-PD-1 immunotherapy
Must have received and progressed on a PD-1 blocking antibody such as pembrolizumab or nivolumab.
BRAF-mutated: prior targeted therapy
If the tumor has a BRAF mutation, a prior BRAF/MEK inhibitor is also required.
Adequate organ function
Kidney, liver, and cardiac function evaluated to confirm ability to tolerate conditioning and infusion phases.
Accessible tumor tissue
A biopsiable lesion from which viable TIL cells can be collected and expanded.
Reading the Evidence Honestly
The pivotal trial showed ~31% objective response rate. That means most patients did not respond โ which is worth stating directly. What it is, in a population with few other options, is a real chance at a meaningful response for roughly one in three patients. In that context, 31% carries genuine clinical weight. Age alone typically does not disqualify someone โ biological fitness and organ health tell a more useful story.
Related TIL Therapy Topics
Explore more across the CancerFax TIL Therapy guide series.
Frequently Asked Questions
Melanoma and TIL Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is TIL Therapy an Option for Your Melanoma?
Upload your medical reports for a specialist case evaluation. We will assess your eligibility for lifileucel and other TIL therapy programs based on your specific diagnosis and history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.